Munich – Formycon AG (ISIN: DE000A1EWVY8/ WKN: A1EWVY) and its license partner Bioeq AG announce that the marketing authorization application (MAA) for FYB201, Formycon’s biosimilar candidate to Lucentis(R) (ranibizumab), has been submitted to the European Medicines Agency (EMA).

Lucentis(R) is used in the treatment of neovascular (wet) macular degeneration and other serious eye diseases. It inhibits vascular endothelial growth factor (VEGF), which is responsible for the excessive formation of blood vessels in the retina.

The commercialization of FYB201 in Europe will be performed by Teva Pharmaceutical Industries Ltd., which has acquired the distribution rights under an exclusive strategic partnership from Bioeq AG.

1)Lucentis(R) is a registered trademark of Genentech Inc.